High-Frequency Repetitive Transcranial Magnetic Stimulation Assists In Smoking Cessation
Cigarette smoking is a major public health problem causing significant morbidity and mortality. Yet, smoking cessation therapies are often ineffective at helping smokers break their addiction.
The mesolimbic dopaminergic reward system plays a crucial role in mediating the reinforcing effects of nicotine. Recently, acute high frequency repetitive transcranial magnetic stimulation (rTMS) of frontal brain regions has been shown to efficiently modulate the mesolimbic dopamine systems in both animals and humans. For this reason, we investigated whether 10 high-frequency (10Hz) rTMS treatments over the left dorsolateral prefrontal cortex can help people to withdraw smoking in comparison to placebo rTMS.
Smokers seeking to quit are recruited through newspaper advertisements. Participants were randomized to 10 days of either real or placebo high frequency rTMS.
|Heavy Smoking||Device: Transcranial Magnetic Stimulation 10Hz Device: Magnetic stimulation using a special sham coil|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
- number of cigarettes smoked
|Study Start Date:||July 2005|
Active Comparator: Real high frequency rTMS
The patients will undergo a series of treatments of high frequency rTMS
Device: Transcranial Magnetic Stimulation 10Hz
3. rTMS subjects will receive 20 trains of rTMS at a rate of 10 Hz for 6 seconds (1200 pulses/session). Pulses will be administered over the left dorsolateral prefrontal cortex, defined as 5 cm anterior and in a parasagital plane to the point of maximum stimulation of the abductor pollicis muscle. Pulse intensity will be set at 100% motor threshold.
Sham Comparator: Sham high frequency rTMS
The patients will receive a series of sham treatments.
Device: Magnetic stimulation using a special sham coil
Sham stimulation will be given at the same location as the active, with special sham coil.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00284219
|Sheba Medical Center|
|Ramat Gan, Israel, 52621|
|Principal Investigator:||Revital A Amiaz, MD||Sheba Medical Center|
|Study Director:||Abraham Zangen, Phd||Weizmann Institute of Science|